+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients



Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients



Zhonghua Yi Xue Za Zhi 96(12): 940-943



To retrospectively analyze the relevance between DNA topoisomerase Ⅱ alpha (TOP2A), epidermal growth factor receptor (EGFR) gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer (TNBC) patients. A total of 53 women with triple negative breast cancer who underwent docetaxel plus epirubicin as neoadjuvant chemotherapy were included in this study. The gene detection was done in the samples before chemotherapy by DNA chip technology. The relevance between TOP2A, EGFR gene expression and efficacy, pathological complete response (pCR) rate of neoadjuvant chemotherapy were retrospectively analyzed. The high expression rate of TOP2A in all the TNBC patients was 35.8% (19/53), while the rate of EGFR was 39.6% (21/53). The overall pCR rate of TNBC patients who underwent docetaxel plus epirubicin as neoadjuvant chemotherapy was 18.9% (10/53). The pCR rate was 31.6% (6/19) in TNBC patients whose TOP2A expression was high, compared to 11.8% (4/34) in whose was low (P>0.05). The pCR rate was 28.6% (6/21) in TNBC patients whose EGFR expression was high, compared to 12.5% (4/32) in whose was low (P>0.05). The pCR rate was 75.0% (6/8) in TNBC patients whose TOP2A, EGFR expression were both high, and was significantly higher than that in all the TNBC patients (P<0.01). Efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in TNBC patients can be predicted by detecting TOP2A, EGFR gene expression. The result may contribute to the development of more individualized neoadjuvant chemotherapy.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 058733745

Download citation: RISBibTeXText

PMID: 27045718


Related references

Efficacy and safety of docetaxel combined with oxaliplatin as a neoadjuvant chemotherapy regimen for Chinese triple-negative local advanced breast cancer patients. A prospective, open, and unicentric Phase II clinical trial. American Journal of Clinical Oncology 36(6): 545-551, 2014

Phase II trial of sequential dose-dense epirubicin/cyclophosphamide (E/C) followed by docetaxel/capecitabine (D/X) as adjuvant or neoadjuvant chemotherapy for patients with HER2-negative breast cancer (BC). Journal of Clinical Oncology 26(15_Suppl): 635-635, 2016

Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors. Drugs in R&d 11(2): 147-157, 2012

PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer. Neoplasma 61(4): 461-467, 2014

Pik3Ca mutations are apredictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer. Neoplasma 61(4): 461-467, 2014

Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer. Oncotargets and Therapy 9: 3443-3450, 2016

Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 153(1): 13-17, 2009

CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients. Medical Oncology 28(Suppl. 1): S129-S134, 2012

Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer. Japanese Journal of Clinical Oncology 41(7): 867-875, 2011

Efficacy and influence of neoadjuvant epirubicin/vinorelbine chemotherapy (EN) on molecular markers in inflammatory breast cancer (IBC) and preliminary results of a randomized study testing as adjuvant chemotherapy the same EN-combination versus docetaxel (TXT). Journal of Clinical Oncology 23(16_Suppl): 886-886, 2016

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. Bmc Cancer 7: 203, 2007

A New Gene Expression Signature for Triple Negative Breast Cancer Using Frozen Fresh Tissue before Neoadjuvant Chemotherapy. Molecular Medicine 23: 101-111, 2017

Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. Clinical Cancer Research 23(3): 649-657, 2016

Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the Natt trial in triple negative or Her2 positive breast cancer. Breast Cancer Research and Treatment 142(3): 549-558, 2013

Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer. Breast Cancer Research and Treatment 142(3): 549-558, 2014